Claims
- 1. A chimeric viral vector comprising:
a functional packaging signal derived from a first virus having no integration means; and an integration means derived from a second, integrating virus.
- 2. The chimeric viral vector of claim 1, wherein the first virus is a virus capable of efficiently infecting a host.
- 3. The chimeric viral vector of claim 1 or 2, wherein the first virus is an adenovirus.
- 4. The chimeric viral vector of claim 1, claim 2, or claim 3 wherein the second, integrating virus is an adeno associated virus.
- 5. The chimeric viral vector of claim 4, further comprising a sequence encoding a functional adeno associated virus rep gene.
- 6. The chimeric viral vector of claiml, claim 2, claim 3, claim 4 or claim 5 further comprising a nucleic acid sequence of interest.
- 7. The chimeric viral vector of claim 6, wherein the nucleic acid sequence of interest comprises one or more genes.
- 8. The chimeric viral vector of claim 6, wherein the nucleic acid sequence of interest encodes a sequence chosen from a group consisting of antisense sequences and co-suppressing sequences.
- 9. The chimeric viral vector of claim 6, claim 7, or claim 8 further comprising regulatory elements for expressing the nucleic acid sequence of interest.
- 10. The chimeric viral vector of claim 1, claim 2, claim 3, claim 4, claim 5, claim 6, claim 7, claim 8, or claim 9 further comprising a suicide gene.
- 11. A virus-like particle comprising a chimeric viral vector, the chimeric viral vector comprising:
a functional packaging signal derived from a first virus having no integration means; and an integration means derived from a second, integrating virus.
- 12. The virus-like particle of claim 11, further comprising an adenovirus-like particle.
- 13. A method for producing a virus-like particle comprising a chimeric viral vector, the method comprising:
providing a cell with viral vector comprising
a functional packaging signal derived from a first virus having no integration means, and an integration means derived from a second, integrating virus; and providing said cell with elements necessary for producing said virus-like particle.
- 14. The method according to claim 13, wherein a first element of said elements necessary for production of said virus-like particle is present in said vector and a second element of said elements necessary for production of said virus-like particle is present in a packaging vector present in said cell.
- 15. The method according to claim 13, wherein said elements necessary for production of said virus-like particle are present on a packaging vector present in said cell.
- 16. A packaging cell comprising genetic elements resulting in production of a virus-like particle including a chimeric viral vector having a functional packaging signal derived from a first virus lacking an integration means and an integration means derived from a second, integrating virus.
- 17. The packaging cell of claim 16 further comprising the vector according to any one of claims 1-10.
- 18. A cell comprising:
a chimeric viral vector comprising a functional packaging signal derived from a first virus lacking integration means and an integration means derived from a second, integrating virus.
- 19. A virus-like particle according to claim 11 or 12 for use as a pharmaceutical.
- 20. A method for treatment of a host, said method comprising:
providing a host exhibiting a dysfunction selected from a group consisting of inherited diseases, malignancies, and genetic deficiencies; providing a virus-like particle comprising a chimeric viral vector including a functional packaging signal derived from a first virus having no integration means and an integration means derived from a second, integrating virus; and introducing said virus-like particle into said host.
- 21. The virus-like particle of claim 11 or 12 for use as a means for permanent genetic modification of a cell.
- 22. The virus-like particle of claim 11 or 12 for use as a means for making transgenic organisms.
- 23. An rAAV nucleic acid comprising a nucleic acid sequence larger than 6.5 kb flanked by and physically linked with two ITRs, each of said two ITRs comprising an ITR selected from a group consisting of an AAV-ITR, a functional part of an AAV-ITR, and a derivative of an AAV-ITR.
- 24. A method for the replication of an rAAV nucleic acid, the method comprising:
providing a cell with proteins encoded by at least a portion of an AAV-rep gene, at least a portion of a protein encoded by an adenovirus region selected from a group of adenovirus regions consisting of E1 regions, E2 regions, and E4 regions; and providing said cell with a nucleic acid comprising an rAAV nucleic acid larger than 6.5 kb and being flanked by two AAV-ITR.
- 25. The method according to claim 24, wherein providing said cell comprises providing a cell further comprising RNA encoded by at least a portion of an adenovirus VA-region.
Priority Claims (1)
Number |
Date |
Country |
Kind |
97204085.1 |
Dec 1997 |
EP |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of co-pending application Ser. No. 09/599,488, filed Jun. 23, 2000 (the contents of the entirety of which is incorporated by this reference), now U.S. Pat. No. ______, which is a continuation of pending application PCT/NL98/00731 filed on Dec. 23, 1998, designating the United States of America. Applicants hereby specifically incorporate the accompanying sequence listing.
Continuations (2)
|
Number |
Date |
Country |
Parent |
09599488 |
Jun 2000 |
US |
Child |
10196688 |
Jul 2002 |
US |
Parent |
PCT/NL98/00731 |
Dec 1998 |
US |
Child |
09599488 |
Jun 2000 |
US |